Grifols | GRFS - Cost Of Sales

Stock Price
7.75
Daily Change
-0.12 -1.52%
Monthly
-17.55%
Yearly
-1.90%
Q1 Forecast
7.59

Grifols reported EUR1.51B in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Alaunos Therapeutics USD 0 18K Sep/2024
aTyr Pharma USD 3.34M 18.79M Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Grifols EUR 1.51B 184.45M Dec/2025
Infinity Pharmaceuticals USD 352K 89K Jun/2023
Minerva Neurosciences 386K 31K Jun/2024
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
TherapeuticsMD USD -11.99M 12.34M Dec/2022